<SEC-DOCUMENT>0001437749-25-023232.txt : 20250909
<SEC-HEADER>0001437749-25-023232.hdr.sgml : 20250909
<ACCEPTANCE-DATETIME>20250722163353
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001437749-25-023232
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250722

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Monopar Therapeutics
		CENTRAL INDEX KEY:			0001645469
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				320463781
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		1000 SKOKIE BLVD SUITE 350
		CITY:			WILMETTE
		STATE:			IL
		ZIP:			60091
		BUSINESS PHONE:		8473880349

	MAIL ADDRESS:	
		STREET 1:		1000 SKOKIE BLVD SUITE 350
		CITY:			WILMETTE
		STATE:			IL
		ZIP:			60091
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<html><head>
	<title>mnpr20250721_corresp.htm</title>

	<!-- Generated by ThunderDome Portal - 7/21/2025 8:53:36 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: col-resize;">
<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div style="text-align: center;"><img alt="mono.jpg" src="mono.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">July 22, 2025</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">United States Securities and Exchange Commission</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Division of Corporation Finance</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Office of Life Sciences</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">100 F Street, N.E.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Washington, D.C. 20549</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Attention:</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Tyler Howes</p>

			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Alan Campbell</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 45pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Re:</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Monopar Therapeutics Inc.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 45pt;"><b>Form 10-K for Fiscal Year Ended December 31, 2024</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 45pt;"><b>Filed March 31, 2025</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 45pt;"><b>File No. 001-39070</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To the addressees set forth above:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On behalf of Monopar Therapeutics Inc. (the &#8220;Company&#8221;), set forth below is the Company&#8217;s response to the comments received from the Staff of the Division of Corporation Finance (the &#8220;Staff&#8221;) of the Securities and Exchange Commission in its letter to the Company dated July 16, 2025, relating to the Company&#8217;s 10-K for the fiscal year ended December 31, 2024, filed on March 31, 2025 (the &#8220;Form 10-K&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the Staff&#8217;s convenience, each response below is preceded by the exact text of the corresponding comment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Form 10-K for Fiscal Year Ended December 31, 2024</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>Item 1. Business</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>Our Product Pipeline, page 7</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We note your inclusion of two programs named &#8220;Early Pipeline&#8221; in your pipeline table on page 7. Given the limited disclosure related to these two programs, please tell us why they are sufficiently material to your business to warrant inclusion in your pipeline table. In future filings, please revise to provide more fulsome disclosure related to these two programs, including any development steps you have undertaken and disclose the individual compounds used in each program. Alternatively, remove any programs that are not currently material to your business from your pipeline table in future filings.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Response to Comment No. 1:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company respectfully acknowledges the Staff&#8217;s comment and advises the Staff that in future filings, beginning with its Form 10-Q for the quarter ended June 30, 2025, the Company will remove from its pipeline table any programs that are not currently material to its business, including the two &#8220;Early Pipeline&#8221; programs referenced above.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>MNPR-101 for Radiopharmaceutical Use, page 8</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Please remove your reference here and on page 57 to MNPR-101 being a &#8220;first-in-class&#8221; monoclonal antibody that targets the urokinase plasminogen activator receptor in future filings, as this statement is speculative in light of the current regulatory status of your clinical candidate.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Response to Comment No. 2:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company respectfully acknowledges the Staff&#8217;s comment and advises the Staff that in future filings, beginning with its Form 10-Q for the quarter ended June 30, 2025, the Company will remove any references to MNPR-101 being a &#8220;first-in-class&#8221; monoclonal antibody that targets the urokinase plasminogen activator receptor.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>License, Development and Collaboration Agreements</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>Alexion, AstraZeneca Rare Disease, page 10</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Please revise future filings to disclose all the material terms of your Alexion licensing agreement including the aggregate amount paid to date under this agreement and any term and termination provisions. Please also ensure that you limit any discussion of royalty rate ranges payable under this agreement to ten percentage points in future filings.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Response to Comment No. 3:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company respectfully acknowledges the Staff&#8217;s comment and advises the Staff that in future filings, beginning with its Form 10-Q for the quarter ended June 30, 2025, the Company will: (i) disclose all material terms of its Alexion licensing agreement, including the aggregate amount paid to date under this agreement and any term and termination provisions; and (ii) limit any discussion of royalty rate ranges payable under this agreement to a range not exceeding ten percentage points.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company further respectfully acknowledges that it and its management are responsible for the accuracy and adequacy of the disclosures in its filings, notwithstanding any review, comments, action or absence of action by the Staff.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Sincerely,</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">/s/&nbsp;Quan Vu</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Quan Vu</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chief Financial Officer</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Monopar Therapeutics Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">cc:</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">John Harrington, Baker &amp; Hostetler LLP</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt;">Sean Cheatle, Baker &amp; Hostetler LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>mono.jpg
<TEXT>
begin 644 mono.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MBBB@ HKS/PK\7;3Q%\4M5\.#:EB 8],N#Q]IDBR)@#WZY'LIKTRG:P!1112
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M44C.J+EV"CU)Q0 M%%(SJBY=@H]2<4 +10"",@Y%% !12*ZMG:P;!P<'I2T
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M!9CT  %:WQ'TZ73?$FB7][8S:CH5G D3Q+G *DY#=AGY>O7&*FS;AS/WM?\
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MZM+HBUOFAEBN+.0Q75M(LT$@ZI(IRI_.OL#P!XN@\;^"['68@J32+LN80?\
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
